Drug intelligence / Profile preview

LADAVRU

Development stage: Preclinical
Lead developer: Hoverink Biotechnologies
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

LADAVRU is an investigational small molecule drug candidate being developed by Hoverink Biotechnologies as a proprietary opioid alternative. It is a formulation of dronabinol, a synthetic cannabinoid, combined with citric acid and mannitol, designed for delivery as an intravenous injection or a solid preparation. The drug is currently in pre-clinical development for the treatment of chronic pain, neuropathy, and nausea and discomfort associated with chemotherapy. It is also being explored for broader applications in conditions such as cancer, cirrhosis, cirrhosis ascites, AIDS, and specifically for relapsed or refractory acute myeloid leukemia (AML) in patients treated with anthracyclines.

Brand names: LADAVRU

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on LADAVRU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LADAVRU.

Explore the full profile